JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263375

Human SUGP2 (SFRS14) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SUGP2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 459 bp deletion in exon3.

View Alternative Names

Arginine/serine-rich-splicing factor 14, DKFZp779L2418, KIAA0365, SUGP2_HUMAN, SURP and G-patch domain-containing protein 2, Splicing factor, Splicing factor, arginine/serine-rich 14, arginine/serine-rich 14

1 Images
Sanger Sequencing - Human SUGP2 (SFRS14) knockout HeLa cell lysate (AB263375)
  • Sanger seq

Unknown

Sanger Sequencing - Human SUGP2 (SFRS14) knockout HeLa cell lysate (AB263375)

Homozygous : 459 bp deletion in exon3

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 459 bp deletion in exon3.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263375-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SUGP2 knockout HeLa cell lysate", "number":"AB263375-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB263375-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
SUGP2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SFRS14 also known as SUGP2 is a protein involved in RNA splicing processes. It facilitates the assembly of spliceosomal complexes which are important in removing introns from pre-mRNA transcripts. The molecular mass of SFRS14 is approximately 111 kDa. This protein expresses widely in human tissues with significant expression in the brain heart and reproductive tissues. Its function in these tissues indicates it plays an important role in post-transcriptional gene regulation.
Biological function summary

SFRS14 influences the regulation of alternative splicing by interacting with other splicing factors. It acts as part of the spliceosome complex which is responsible for the precise cutting and joining of exons from mRNA precursors. SFRS14 ensures the correct splicing of transcripts related to various cellular functions. Its role in alternative splicing helps generate protein diversity which is essential in maintaining cellular processes and adaptation to different physiological conditions.

Pathways

This protein takes part in the mRNA processing pathway and the gene expression pathway. In the mRNA processing pathway SFRS14 assists in accurately assembling the spliceosome ensuring proper splicing of precursor mRNA. Relating to other proteins in these pathways SFRS14 interacts with members of the SR protein family which includes proteins like SFRS1 and SFRS2. These interactions highlight its contribution to the regulation of gene expression through mRNA maturation.

Several cases relate improper function of SFRS14 to specific pathologies like cancer and neurological conditions. In cancer aberrant alternative splicing events which involve SFRS14 alter the expression of genes that control cell growth and apoptosis. The SFRS14 protein connects to the BCL2 family of proteins which play a role in apoptotic processes in cancer cells. Similarly disruptions in SFRS14 function have been observed in neurodegenerative diseases where it may affect neuronal survival and plasticity due to faulty splicing of essential neuronal transcripts.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com